http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Dermira (DERM) Says QBREXZA Cloth Is Now Available in Pharmacies Nationwide
-
Dermira’s QBREXZA™ (glycopyrronium) Cloth Is Now Available in Pharmacies Nationwide for the Treatment of Primary Axillary Hyperhidrosis
-
Dermira to Present at Cantor 2018 Global Healthcare Conference
-
Dermira (DERM) Highlights New Pediatric Efficacy & Safety Data for Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis at EADV Congress
-
Dermira Presents New Pediatric Efficacy and Safety Data for Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis at the European Academy of Dermatology and Venereology Congress
-
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Dermira Provides Launch Readiness Update for QBREXZA™ (glycopyrronium) Cloth for Primary Axillary Hyperhidrosis
-
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Dermira Reports Second Quarter 2018 Financial Results and Provides Corporate Update
-
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Dermira (DERM) Announces FDA Approval for Qbrexza Cloth to Treat Primary Axillary Hyperhidrosis
-
Dermira Receives FDA Approval for Qbrexza™ (glycopyrronium) Cloth to Treat Primary Axillary Hyperhidrosis
-
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Dermira to Present at Jefferies 2018 Global Healthcare Conference
-
Dermira to Host Analyst & Investor Day on May 24, 2018
-
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Dermira Reports First Quarter 2018 Financial Results and Provides Corporate Update
-
Dermira and Cameran Eubanks Team Up to Raise Awareness of Excessive Sweating for the 15 Million People Living with the Condition in the U.S.
-
Dermira and Cameran Eubanks Team Up to Raise Awareness of Excessive Sweating for the 15 Million People Living with the Condition in the U.S.
-
Dermira to Present at Deutsche Bank 43rd Annual Healthcare Conference
-
Christopher Horan Joins Dermira as Chief Technical Operations Officer
-
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Dermira to Present at 17th Annual Needham Healthcare Conference
-
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Dermira to Present at Cowen & Company 38th Annual Healthcare Conference
-
Dermira (DERM) Says Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpoints
-
Dermira’s Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpoints
-
Dermira Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
-
Dermira (DERM) Reports New Data from Glycopyrronium Tosylate (formerly DRM04) Phase 3 Clinical in Pediatric Patients with Axillary Hyperhidrosis
-
New Data in Pediatric Patients with Axillary Hyperhidrosis Presented During Late-Breaking Research Forum at the 76th Annual Meeting of the American Academy of Dermatology
-
Dermira Showcases Commitment to Hyperhidrosis Education and Treatment at Leading Dermatology Conference
-
Dermira to Present at Leerink Partners 7th Annual Global Healthcare Conference
-
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Dermira (DERM) Commences Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
-
Dermira Initiates Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
-
Dermira to Present at Upcoming Investor Conferences in November
-
Dermira (DERM), UCB Agree to End Collaboration Agreement for CIMZIA
-
Dermira Reports Third Quarter 2017 Financial Results and Announces that FDA Accepts New Drug Application for Glycopyrronium Tosylate for the Treatment of Patients with Primary Axillary Hyperhidrosis
-
Dermira and UCB Agree to End Collaboration Agreement for CIMZIA
-
Dermira (DERM) Announces New Long-Term Safety Data for Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis
-
Dermira Highlights New Long-Term Safety Data for Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis at Fall Clinical Dermatology Conference
-
Dermira (DERM) Says New CIMZIA Findings Presented at EADV
-
New CIMZIA® (certolizumab pegol) Findings Presented at European Academy of Dermatology and Venereology (EADV) Congress
-
UCB and Dermira Announce U.S. and EU Regulatory Submissions for CIMZIA® (certolizumab pegol) for the treatment of Moderate-to-Severe Chronic Plaque Psoriasis
-
New CIMZIA® (certolizumab pegol) data in moderate-to-severe plaque psoriasis and psoriatic arthritis presented at American Academy of Dermatology 2017 Annual Meeting
-
JANA Partners Enters Aetna (AET), Bristol-Myers Squibb (BMY), Lamb Weston (LW), Salesforce (CRM) (more...) - 13F
-
Final CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Primary Efficacy Endpoint in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
-
Dermira (DERM) Announces CIMZIA Phase 3 Met co-Primary Efficacy Endpoints in Certain Plaque Psoriasis
-
Second CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
-
JANA Partners Enters Kate Spade (KATE), Select Medical (SEM), Twitter (TWTR) (more...)
